[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640953":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":55,"collaborators":29,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":29,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":83,"whyStopped":29,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Emory University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Baricitinib","EXPERIMENTAL","Participants will receive 1 tablet\u002Fd of 2 mg baricitinib at baseline. For participants who do not exhibit a clinical response at 4 Weeks (a 50% reduction in HAM-D scores), the dose will be increased to 4 mg\u002Fday (2 tablets\u002Fd of baricitinib), as tolerated.",[13],"Drug: Baricitinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients. Baricitinib will be dispensed every other week at the Week 2, 4, and 6 study visits. Participants who do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) at Week 4 will be increased to 4 mg\u002Fday of baricitinib (2 x 2 mg tablets). A virtual follow-up visit will be conducted at Week 1 to assess safety and tolerability in all patients, and at Week 5 in patients who increase the dose.",[9],[20],"Olumiant",[22],{"name":23,"affiliation":5,"role":24},"Andrew H Miller, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","404-727-8260",null,"amill02@emory.edu",[32,45,50],{"facility":33,"status":29,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":29},"Emory Clinic, Emory University Hospital","Atlanta","Georgia","30322","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-84.38798,33.749,{"lat":43,"lon":42},{"facility":46,"status":29,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":47,"geoPoint":49,"contacts":29},"Emory School Of Medicine",{"type":40,"coordinates":48},[42,43],{"lat":43,"lon":42},{"facility":5,"status":29,"city":34,"state":35,"zip":51,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":54,"contacts":29},"30329",{"type":40,"coordinates":53},[42,43],{"lat":43,"lon":42},{"type":24,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Andrew H Miller","Professor of Medicine","100640953","phase-2-jak-signaling-in-depression-and-cognition-in-male-football-players-100640953",false,"NCT07608796","JAK Signaling in Depression and Cognition in Male Football Players","JAK DC in Play","Inclusion Criteria:\n\n* willing and able to give written informed consent\n* males\n* \\>10 years of playing football (at least 1 year in the NFL)\n* 40-55 years of age\n* Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V\n* score of \\>10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry\n* off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes)\n* CRP ≥3 mg\u002FL\n* PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2\n\nExclusion Criteria:\n\n* current or history of past autoimmune disorder\n* history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection\n* history of any type of cancer requiring treatment with more than minor surgery\n* unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)\n* significant hematological abnormalities at screening (ANC \\\u003C 1500, Hgb\\\u003C10, platelet\\\u003C 100,000)\n* history of progressive multifocal leukoencephalopathy\n* history of deep venous thrombosis\n* history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK)\n* major surgery within 6 months before screening, or will require major surgery during the study\n* current or recent (\\\u003C4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection\n* symptomatic herpes zoster infection at or within 12 weeks of study start\n* history of disseminated\u002Fcomplicated herpes zoster (for example, ophthalmic zoster or CNS involvement)\n* cirrhosis of the liver from any cause\n* Additional exclusion criteria apply",true,"MALE","40 Years","55 Years",{"count":70,"type":71},30,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.",[77,78],"Depressive Symptoms","Cognitive Symptom",[80,81,82],"Football player","Inflammation","NFL","NOT_YET_RECRUITING","2026-05-20",{"date":86,"type":87},"2026-05-27","ACTUAL",{"date":89,"type":71},"2026-06",{"date":91,"type":71},"2027-10",{"name":5,"class":6},3]